These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10632319)

  • 41. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
    ; Fouladi M; Furman WL; Chin T; Freeman BB; Dudkin L; Stewart CF; Krailo MD; Speights R; Ingle AM; Houghton PJ; Wright J; Adamson PC; Blaney SM
    J Clin Oncol; 2006 Aug; 24(22):3678-85. PubMed ID: 16877737
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Uckun FM; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Manivel C; Irvin JD; Myers DE; Gunther R
    Blood; 1992 Jun; 79(12):3116-29. PubMed ID: 1375841
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I clinical trial of serotherapy in patients with acute myeloid leukemia with an immunoglobulin M monoclonal antibody to CD15.
    Ball ED; Selvaggi K; Hurd D; Herzig R; Clark L; Malley V; Persichetti J; deMagelhaus-Silverman M
    Clin Cancer Res; 1995 Sep; 1(9):965-72. PubMed ID: 9816068
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule.
    Myers DE; Yanishevski Y; Masson E; Irvin JD; Evans WE; Uckun FM
    Leuk Lymphoma; 1995 Jun; 18(1-2):93-102. PubMed ID: 8580835
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma.
    Stapleton FB; Strother DR; Roy S; Wyatt RJ; McKay CP; Murphy SB
    Pediatrics; 1988 Dec; 82(6):863-9. PubMed ID: 3186376
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside.
    Messinger Y; Yanishevski Y; Avramis VI; Ek O; Chelstrom LM; Gunther R; Myers DE; Irvin JD; Evans W; Uckun FM
    Clin Cancer Res; 1996 Sep; 2(9):1533-42. PubMed ID: 9816330
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase.
    Ek O; Gaynon P; Zeren T; Chelstrom LM; Myers DE; Uckun FM
    Leuk Lymphoma; 1998 Sep; 31(1-2):143-9. PubMed ID: 9720724
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins.
    Uckun FM; Jaszcz W; Ambrus JL; Fauci AS; Gajl-Peczalska K; Song CW; Wick MR; Myers DE; Waddick K; Ledbetter JA
    Blood; 1988 Jan; 71(1):13-29. PubMed ID: 3257143
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (Tomudex) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia.
    Ek O; Reaman GH; Crankshaw DL; Chelstrom LM; Myers DE; Uckun FM
    Leuk Lymphoma; 1998 Feb; 28(5-6):509-14. PubMed ID: 9613980
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Targeted killing of the Nalm-6 cells with 2E8-Genistein immunotoxin and its mechanism].
    Chen YH; Tang YM; Shen HQ; Song H; Yang SL; Shi SW; Qian BQ; Xu WQ; Ning BT
    Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):57-61. PubMed ID: 19573385
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin.
    Waurzyniak B; Schneider EA; Tumer N; Yanishevski Y; Gunther R; Chelstrom LM; Wendorf H; Myers DE; Irvin JD; Messinger Y; Ek O; Zeren T; Langlie MC; Evans WE; Uckun FM
    Clin Cancer Res; 1997 Jun; 3(6):881-90. PubMed ID: 9815763
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.
    Bachanova V; Frankel AE; Cao Q; Lewis D; Grzywacz B; Verneris MR; Ustun C; Lazaryan A; McClune B; Warlick ED; Kantarjian H; Weisdorf DJ; Miller JS; Vallera DA
    Clin Cancer Res; 2015 Mar; 21(6):1267-72. PubMed ID: 25770294
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.
    Uckun FM; Chelstrom LM; Irvin JD; Finnegan D; Gunther R; Young J; Kuebelbeck V; Myers DE; Houston LL
    Blood; 1992 May; 79(10):2649-61. PubMed ID: 1375109
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
    Gunther R; Chelstrom LM; Tuel-Ahlgren L; Simon J; Myers DE; Uckun FM
    Blood; 1995 May; 85(9):2537-45. PubMed ID: 7537120
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.
    Grossbard ML; Lambert JM; Goldmacher VS; Spector NL; Kinsella J; Eliseo L; Coral F; Taylor JA; Blättler WA; Epstein CL
    J Clin Oncol; 1993 Apr; 11(4):726-37. PubMed ID: 7683045
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
    Tan CT; Hancock C; Steinherz PG; Steinherz LJ; Sorell M; Chan KW; Mondora A; Miller DR
    Cancer Res; 1982 Apr; 42(4):1579-81. PubMed ID: 6895864
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin.
    Frankel AE; Laver JH; Willingham MC; Burns LJ; Kersey JH; Vallera DA
    Leuk Lymphoma; 1997 Jul; 26(3-4):287-98. PubMed ID: 9322891
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of temozolomide in a SCID mouse model of human B-cell precursor leukemia.
    Messinger Y; Reaman GH; Ek O; Uckun FM
    Leuk Lymphoma; 1999 Apr; 33(3-4):289-93. PubMed ID: 10221508
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials.
    Myers DE; Irvin JD; Smith RS; Kuebelbeck VM; Uckun FM
    J Immunol Methods; 1991 Feb; 136(2):221-37. PubMed ID: 1705571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.